These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26882502)

  • 1. More effective drugs lead to harder selective sweeps in the evolution of drug resistance in HIV-1.
    Feder AF; Rhee SY; Holmes SP; Shafer RW; Petrov DA; Pennings PS
    Elife; 2016 Feb; 5():. PubMed ID: 26882502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clarifying role of time series data in the population genetics of HIV.
    Feder AF; Pennings PS; Petrov DA
    PLoS Genet; 2021 Jan; 17(1):e1009050. PubMed ID: 33444376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Resistance Evolution in HIV in the Late 1990s: Hard Sweeps, Soft Sweeps, Clonal Interference and the Accumulation of Drug Resistance Mutations.
    Williams KA; Pennings P
    G3 (Bethesda); 2020 Apr; 10(4):1213-1223. PubMed ID: 32075854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soft shoulders ahead: spurious signatures of soft and partial selective sweeps result from linked hard sweeps.
    Schrider DR; Mendes FK; Hahn MW; Kern AD
    Genetics; 2015 May; 200(1):267-84. PubMed ID: 25716978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A model of directional selection applied to the evolution of drug resistance in HIV-1.
    Seoighe C; Ketwaroo F; Pillay V; Scheffler K; Wood N; Duffet R; Zvelebil M; Martinson N; McIntyre J; Morris L; Hide W
    Mol Biol Evol; 2007 Apr; 24(4):1025-31. PubMed ID: 17272680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergence and epidemiology of resistance in the nucleoside-experienced HIV-infected population.
    Pillay D
    Antivir Ther; 2001; 6 Suppl 3():15-24. PubMed ID: 11678470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolutionary pathways of transmitted drug-resistant HIV-1.
    Pingen M; Nijhuis M; de Bruijn JA; Boucher CA; Wensing AM
    J Antimicrob Chemother; 2011 Jul; 66(7):1467-80. PubMed ID: 21502281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection and Classification of Hard and Soft Sweeps from Unphased Genotypes by Multilocus Genotype Identity.
    Harris AM; Garud NR; DeGiorgio M
    Genetics; 2018 Dec; 210(4):1429-1452. PubMed ID: 30315068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Consequences of Antiviral Therapy on HIV-1.
    Arenas M
    Comput Math Methods Med; 2015; 2015():395826. PubMed ID: 26170895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV drug resistance and you. Resistance testing in experienced patients. Considerations when changing drugs.
    Posit Aware; 2006; Spec No():17-22. PubMed ID: 16596730
    [No Abstract]   [Full Text] [Related]  

  • 12. Soft Selective Sweeps in Evolutionary Rescue.
    Wilson BA; Pennings PS; Petrov DA
    Genetics; 2017 Apr; 205(4):1573-1586. PubMed ID: 28213477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low Incidence of HIV-1C Acquired Drug Resistance 10 Years after Roll-Out of Antiretroviral Therapy in Ethiopia: A Prospective Cohort Study.
    Mulu A; Maier M; Liebert UG
    PLoS One; 2015; 10(10):e0141318. PubMed ID: 26512902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1.
    John M; Moore CB; James IR; Mallal SA
    Antivir Ther; 2005; 10(4):551-5. PubMed ID: 16038481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug resistance is rarely the cause or consequence of long-term persistent low-level viraemia in HIV-1-infected patients on ART.
    Vancoillie L; Mortier V; Demecheleer E; Schauvliege M; Vandekerckhove L; Vogelaers D; Verhofstede C
    Antivir Ther; 2015; 20(8):789-94. PubMed ID: 25945956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Scale-up of antiretroviral treatment in sub-Saharan Africa is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.
    Aghokeng AF; Kouanfack C; Laurent C; Ebong E; Atem-Tambe A; Butel C; Montavon C; Mpoudi-Ngole E; Delaporte E; Peeters M
    AIDS; 2011 Nov; 25(17):2183-8. PubMed ID: 21860346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early selection of resistance-associated mutations in HIV-1 RT C-terminal domains across different subtypes: role of the genetic barrier to resistance.
    Muniz CP; Soares MA; Santos AF
    J Antimicrob Chemother; 2014 Oct; 69(10):2741-5. PubMed ID: 24948706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of repeat genotypic resistance testing and clinical response in patients with three class resistance and virologic treatment failure.
    Badri SM; Adeyemi OM; Max BE; Hota BN; Barker DE
    AIDS Patient Care STDS; 2007 Aug; 21(8):544-50. PubMed ID: 17711379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral Resistance Mutations (revised April 2001).
    ;
    HIV Clin Trials; 2001; 2(4):346-55. PubMed ID: 11590539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.